Zolgensma didn't cause an infant death, AveXis execs say as they spotlight long-term data
Before the recent data manipulation scandal engulfed Novartis’ star gene therapy Zolgensma, the death of an infant in one of their Phase III trials threatened to sound safety alarms about the spinal muscular atrophy treatment. But scientists at the AveXis subsidiary now say an investigation has cleared that particular worry.
Nestled in a lengthy presentation of upbeat data, the update offers some much-needed validation for Zolgensma as execs scramble to rebuild their credibility with both regulators and the general public.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.